GREENVILLE, SC, KIYATEC has secured a $2.5 million investment from Seae Ventures.
KIYATEC has secured a $2.5 million investment from Seae Ventures.
KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company's Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for its investigational drug candidates across the majority of solid tumor types.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about